Clinical Trials Browser

Not yet recruiting × Melanoma × 30 days × Clear all

Cardiofaciocutaneous syndrome, Legius syndrome, Congenital Bone Marrow Failure Syndromes, Melanoma, Cutaneous Malignant, Chordoma, Fanconi Anemia, Melanoma, Neoplasms, Li-Fraumeni Syndrome, Pulmonary Blastoma, Costello Syndrome

NCT07527325 2026-04-22

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

Phase 2 Not yet recruiting

35 enrolled

Dermatologic

Melanoma

NCT07518043 2026-04-15

A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

Phase 1 Not yet recruiting

174 enrolled

DermatologicGenitourinary

Carcinoma, Transitional Cell, Melanoma

NCT07529080 2026-04-14

Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial

Phase NA Not yet recruiting

142 enrolled

DermatologicEndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Melanoma, Testicular Neoplasms, Adenocarcinoma, Follicular

NCT07519655 2026-04-09

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Phase 1 Not yet recruiting

250 enrolled

DermatologicGastrointestinalThoracic

Esophageal Neoplasms, Lung Neoplasms, Melanoma

NCT07517653 2026-04-08

Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

Phase 2 Not yet recruiting

70 enrolled

Dermatologic

Melanoma

NCT07511036 2026-04-06

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

Phase 2 Not yet recruiting

20 enrolled

Dermatologic

Melanoma

NCT07476326 2026-04-03

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

Phase 1 Not yet recruiting

120 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT07501104 2026-03-30

TRIUMPH-AM

Phase 2 Not yet recruiting

30 enrolled

Dermatologic

Melanoma

Clinical Trials

Clinical Genetics Branch Eligibility Screening Survey

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

TRIUMPH-AM